Teva Pharmaceutical Industries (NYSE:TEVA) Price Target Raised to $21.00 at Barclays

Teva Pharmaceutical Industries (NYSE:TEVAGet Free Report) had its price target upped by Barclays from $20.00 to $21.00 in a research note issued to investors on Wednesday, Benzinga reports. The firm presently has an “overweight” rating on the stock. Barclays‘s target price points to a potential upside of 26.43% from the company’s current price.

A number of other research analysts have also recently issued reports on TEVA. Bank of America raised their price target on shares of Teva Pharmaceutical Industries from $18.00 to $21.00 and gave the stock a “buy” rating in a report on Thursday, May 30th. JPMorgan Chase & Co. raised shares of Teva Pharmaceutical Industries from an “underweight” rating to a “neutral” rating and set a $14.00 target price for the company in a report on Friday, March 8th. Piper Sandler reissued an “overweight” rating and set a $20.00 target price (up previously from $19.00) on shares of Teva Pharmaceutical Industries in a report on Monday, May 13th. Finally, StockNews.com cut shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a report on Monday, May 20th. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, Teva Pharmaceutical Industries presently has a consensus rating of “Moderate Buy” and an average target price of $15.88.

Check Out Our Latest Report on Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Trading Down 1.6 %

NYSE TEVA opened at $16.61 on Wednesday. The company has a fifty day simple moving average of $14.97 and a two-hundred day simple moving average of $12.86. The stock has a market cap of $18.62 billion, a P/E ratio of -40.51, a P/E/G ratio of 1.59 and a beta of 0.91. Teva Pharmaceutical Industries has a 12-month low of $7.24 and a 12-month high of $17.39. The company has a current ratio of 0.89, a quick ratio of 0.61 and a debt-to-equity ratio of 2.20.

Teva Pharmaceutical Industries (NYSE:TEVAGet Free Report) last posted its quarterly earnings results on Wednesday, May 8th. The company reported $0.46 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.49 by ($0.03). The company had revenue of $3.82 billion during the quarter, compared to analysts’ expectations of $3.70 billion. Teva Pharmaceutical Industries had a positive return on equity of 37.33% and a negative net margin of 2.88%. On average, analysts forecast that Teva Pharmaceutical Industries will post 2.3 earnings per share for the current year.

Insider Activity

In other news, insider Vikki L. Conway sold 15,219 shares of Teva Pharmaceutical Industries stock in a transaction on Monday, May 13th. The shares were sold at an average price of $16.74, for a total transaction of $254,766.06. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Teva Pharmaceutical Industries news, CAO Amir Weiss sold 15,500 shares of Teva Pharmaceutical Industries stock in a transaction on Wednesday, May 15th. The shares were sold at an average price of $16.80, for a total value of $260,400.00. Following the transaction, the chief accounting officer now directly owns 17,814 shares in the company, valued at $299,275.20. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Vikki L. Conway sold 15,219 shares of Teva Pharmaceutical Industries stock in a transaction on Monday, May 13th. The shares were sold at an average price of $16.74, for a total transaction of $254,766.06. The disclosure for this sale can be found here. Insiders own 0.55% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in TEVA. Private Advisor Group LLC increased its stake in shares of Teva Pharmaceutical Industries by 13.8% during the third quarter. Private Advisor Group LLC now owns 14,770 shares of the company’s stock worth $147,000 after acquiring an additional 1,790 shares during the period. Barclays PLC increased its stake in shares of Teva Pharmaceutical Industries by 6.6% during the third quarter. Barclays PLC now owns 1,118,202 shares of the company’s stock worth $11,405,000 after acquiring an additional 69,502 shares during the period. J.P. Morgan Private Wealth Advisors LLC increased its stake in shares of Teva Pharmaceutical Industries by 33.1% during the third quarter. J.P. Morgan Private Wealth Advisors LLC now owns 20,495 shares of the company’s stock worth $209,000 after acquiring an additional 5,093 shares during the period. Janney Montgomery Scott LLC increased its stake in shares of Teva Pharmaceutical Industries by 0.8% during the third quarter. Janney Montgomery Scott LLC now owns 818,727 shares of the company’s stock worth $8,351,000 after acquiring an additional 6,407 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its stake in shares of Teva Pharmaceutical Industries by 8.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 686,412 shares of the company’s stock worth $7,001,000 after acquiring an additional 52,436 shares during the period. 54.05% of the stock is currently owned by institutional investors and hedge funds.

About Teva Pharmaceutical Industries

(Get Free Report)

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.

Featured Stories

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.